Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 7/20 | 0.56 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.56 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | GRK5 | P34947 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.56 |
| ▸ | ATG7 | O95352 | 1/20 | 0.40 |
| ▸ | UBA7 | P41226 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192208 | 1.00 | NAE1 (0.56) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL192210 | 1.00 | NAE1 (0.56) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL192211 | 1.00 | NAE1 (0.56) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL9947591 | 0.93 | NAE1 (0.55) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL5469913 | 0.93 | NAE1 (0.55) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL9947589 | 0.93 | NAE1 (0.55) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL21273750 | 0.91 | NAE1 (0.54) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL10186312 | 0.91 | NAE1 (0.54) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL192812 | 0.91 | NAE1 (0.52) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL192813 | 0.91 | NAE1 (0.52) | NAE1UBA3UBA6SAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885UBA6 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.